Swedish Orphan Biovitrum AB’s (publ) (Sobi™) CEO Geoffrey McDonough has divested 300,000 of the shares he holds in the company. The sale was made for personal financial reasons. After the transaction, the CEO will hold a total of 347,948 shares in the company.
---
About Sobi™
Sobi™ is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. We also market a portfolio of speciality and rare disease products across Europe, the Middle East, North Africa and Russia for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2015, Sobi had total revenues of SEK 3.2 billion (USD 385 M) and approximately 700 employees. The share (STO: SOBI) is listed on Nasdaq Stockholm.
For more information please contact
| Media relations | Investor relations |
| Charlotte af Klercker, Sr Communications Manager | Jörgen Winroth, Vice President, Head of Investor Relations |
| T: +46-707-297 327 | T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135 |
| [email protected] | [email protected] |
Swedish Orphan Biovitrum AB
Postal address SE-112 76 Stockholm, Sweden
Phone: +46 8 697 20 00 www.sobi.com
We are a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases.
Our therapies are concentrated within the areas of Haematology, Immunology and Specialty Care.
We contribute to societies by improving access to treatment of rare diseases.
Find out more about our business and financial performance.
Here we present our most recent press releases, news articles, and images.
Every day, we work actively to find better ways to understand and meet patient needs.